ERBB2 and neoplasm: Here, through generation of a MED1 mammary gland-specific overexpression mouse model, we further provided strong evidence that MED1 overexpression can promote HER2-driven tumor onset, growth, metastasis, and resistance to anti-HER2 treatment.